Follow The Filings

RYTM Rhythm Pharmaceuticals Inc.

Health Care, filed as RHYTHM PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 1.2%
  • $36M
  • 1 new 1 small

In 2026 Q2 Stanley Druckenmiller opened a position in Rhythm Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 1.2% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 1.2%
  2. Stanley Druckenmiller New 0.43%

Who owns RYTM

Sorted by value, long equity only, as of 2026 Q2.

History
Stanley Druckenmiller, Duquesne Family Office 0.43% New 0.43% 203,618 $23M History
James Silverman, Opaleye Management 1.2%, was 4.7% Small trim −0.4% 122,500 $14M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RYTM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RYTM insider trades
  • None no insider bought on the open market
  • $931K sold by 1 insider outside a trading plan
  • $39.2M sold by 8 insiders under 10b5-1 plans
  1. David P Meeker CEO
    Planned sale
    $5.1M 50,000 shares at $102.67 17% of stake
    Traded Sep 14 Filed Sep 14
    ↗
  2. Hunter C Smith CFO
    Planned sale
    $6.6M 62,774 shares at $105.46 36% of stake
    Traded Aug 31 Filed Sep 1
    ↗
  3. Joseph Shulman Chief Technical Officer
    Planned sale
    $608K 5,079 shares at $119.75 24% of stake
    Traded Aug 13 Filed Aug 17
    ↗
  4. Alastair Garfield Chief Scientific Officer
    Planned sale
    $913K 7,763 shares at $117.57 77% of stake
    Traded Aug 13 Filed Aug 17
    ↗
  5. Jennifer Kayden Lee EVP, Head of North America
    Planned sale
    $8.9M 75,834 shares at $117.38 100% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  6. Yann Mazabraud EVP, Head of International
    Planned sale
    $6.6M 57,000 shares at $116.15 51% of stake
    Traded Aug 12 Filed Aug 14
    ↗
  7. Lynn A. Tetrault Director
    Planned sale
    $3.7M 37,000 shares at $100.32 84% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  8. Christopher Paul German Corporate Controller & CAO
    Sale
    $428K 4,643 shares at $92.21 100% of stake
    Traded May 15 Filed May 19
    ↗
  9. Christopher Paul German Corporate Controller & CAO
    Sale
    $503K 5,614 shares at $89.56 97% of stake
    Traded Mar 4 Filed Mar 6
    ↗
  10. Hunter C Smith CFO
    Planned sale
    $806K 7,954 shares at $101.31 6.7% of stake
    Traded Feb 17–19 Filed Feb 19
    ↗
  11. Hunter C Smith CFO
    Planned sale
    $709K 7,071 shares at $100.21 5.6% of stake
    Traded Feb 10–12 Filed Feb 12
    ↗
  12. Hunter C Smith CFO
    Planned sale
    $703K 6,628 shares at $106.03 5% of stake
    Traded Feb 4–5 Filed Feb 6
    ↗
  13. Pamela J. Cramer Chief Human Resources Officer
    Planned sale
    $372K 3,350 shares at $111.00 14% of stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗
  14. Pamela J. Cramer Chief Human Resources Officer
    Planned sale
    $352K 3,350 shares at $105.00 14% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
    ↗
  15. Pamela J. Cramer Chief Human Resources Officer
    Planned sale
    $2.3M 22,866 shares at $99.00 52% of stake
    Traded Nov 7–10 Filed Nov 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 38 option exercises, 9 share withholdings for taxes, and 2 other transactions.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $77.43M $130.13M $189.76M
Gross profit * $68.13M $116.76M $170.26M
Gross margin * 88.0% 89.7% 89.7%
Net income -$184.68M -$260.6M -$196.54M
Net margin * -238.5% -200.3% -103.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $308.27M $374.2M $466.92M
Total non-current assets * $24.48M $18.07M $13.28M
Total assets $332.74M $392.27M $480.2M
Total current liabilities $55.2M $115.52M $105.94M
Total non-current liabilities * $107.78M $112.21M $104.23M
Total equity $169.76M $21.73M $139.07M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$136.16M -$113.88M -$115.68M
Cash from investing -$5.66M -$48.17M -$137.15M
Cash from financing $74.37M $191.24M $217.96M
Net change in cash -$67.6M $29.19M -$34.78M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.